Concept	Program	2023		2024 J F M A M J J A S O N D		2025			2026 J F M A M J J A S O N D				2027			2028		
	(can be hinden)											D J F M A				J F M A M J J A S O N D		
	egtibatinase iz Replacement Therapy – CBS Enz ravere) Reg Review Protocol Developmen				ase III			DA File Re		Reg Review	g Review		Market Launches					
	SYNT-202 Engineered MET-gamma-lyase (Syntis)	Preclinical POC		IND Studies		Reg Review			DA Reg Review		Phase	Phase II DA		Phase III				
	SYNT-202 (extended release) Engineered MET-gamma-lyase (Syntis)	Discovey				Preclinical POC			Timelines unknown – estima			timated 7-9 ye	ated 7-9 years from IND filing/Ph I Ir			Initiation to market launches		
	Bacterially derived methionases (Petri Bio)	Preclinical PO(IND Studies			Timelines unknown – estimated 7-9 years from IND filing/Ph I Initiation to n launches						Ph I Initiation to marke			
	AAV-CBS Gene transfer (Kruger/Crystal)	Timelii			Timelines ເ	es unknown – estimated 7-9 years from IND filing/Ph I Initiation to market launches												
	Gene editing (Tome Biosciences)	Timelines				POC for HCU once POC established for P unknown – estimated 7-9 years from IND filing/Ph I In						arket launches	1					
Chaperone Therapy	Screening based on fragment x-ray crystallography (McCorvie)		Discove	ovey				elines unknown – estimated 8-10 years from discovery to market launches										
Metabolic Pathway Modification	Formate combined with Betaine (Maclean)	Preclinical POC: I	ND Studies		IND Studies		Reg Rev				Phase I			DA	Reg Rev	Phase II		

*Expected Development timelines Informed by General Industry Assumptions and have not been confirmed by the program sponsors.

Legend: POC – Proof of Concept; IND – Investigational New Drug Application; DA – Data Analysis; F – Filing with Regulatory Agencies; R – Regulatory Review; ML – Market Launches



